Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock

Key Points

• Insider sale: Director Atul Dandekar sold 7,500 shares on April 29 at an average price of $25.37 for $190,275, leaving him with 10,503 shares (a reported 41.66% decrease) and executed under a pre-arranged Rule 10b5-1 plan.
• Stock action and metrics: MAZE rose about 2.6% to $27.27 on above-average volume (860,494 vs. avg. 755,305), with a market cap of $1.36B, a 52-week range of $8.24–$53.65, and the share price trading below its 50- and 200-day moving averages (~$36.92 and $38.05).
• Analyst and company context: The company, a clinical-stage biotech, beat Q1 EPS estimates ($-0.65 vs. $-0.73) but faces a negative full-year EPS outlook, while analysts hold a consensus Buy rating with a $66 average price target amid mixed individual upgrades and downgrades.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the transaction, the insider owned 10,503 shares in the company, valued at approximately $266,461.11. This represents a 41.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Up 2.6%

MAZE stock traded up $0.69 during midday trading on Friday, reaching $27.27. 860,494 shares of the company's stock traded hands, compared to its average volume of 755,305. The firm's fifty day moving average price is $36.92 and its 200-day moving average price is $38.05. Maze Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $53.65. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -8.44 and a beta of 5.16.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. Analysts forecast that Maze Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds have recently made changes to their positions in MAZE. Royal Bank of Canada grew its position in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after buying an additional 363 shares during the period. Ameritas Investment Partners Inc. raised its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after acquiring an additional 738 shares during the period. California State Teachers Retirement System boosted its stake in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after acquiring an additional 766 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in shares of Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock valued at $247,000 after acquiring an additional 931 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Maze Therapeutics during the 4th quarter valued at approximately $39,000.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MAZE. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. Weiss Ratings restated a "sell (d)" rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Truist Financial decreased their price target on Maze Therapeutics from $68.00 to $64.00 and set a "buy" rating for the company in a report on Tuesday, April 14th. Guggenheim increased their price target on Maze Therapeutics from $46.00 to $58.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Finally, Mizuho upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.